The Coalition for Monitoring Biotechnology Activities (CVAB) welcomed, albeit with relief and satisfaction, the decision of the government of Burkina Faso to end Target Malaria project activities throughout the national territory.
“This wise, responsible, and historic decision marks an important step in preserving the scientific and health sovereignty of our country, Burkina Faso. It also demonstrates the authorities’ willingness to opt for solutions that respect public health, the environment, and citizens’ choices,” the group stated.
The CVAB reaffirms that malaria is a national tragedy, causing grief to thousands of families each year. It hopes that the Burkinabe government will intensify the development and implementation of safe, inclusive, and proven public policies for the eradication of the disease.
“Several countries have succeeded in being certified malaria-free thanks to reliable and proven methods. Burkina Faso can also meet this challenge with strategies adapted to its realities.”
The CVAB expresses its deep gratitude to all those who, directly or indirectly, contributed to ensuring that the voice of civil society was heard in this process.
Target Malaria is a research consortium led by Imperial College London, which receives core funding from the Bill and Melinda Gates Foundation to apparently eradicate Malaria in Africa. The first phase of its project in Burkina Faso has been a failure, involving the release of GM mosquitoes.
“We have witnessed strained human capacity on the part of regulatory authorities; a lack of experience, transparency, and compliance with the Convention on Biological Diversity and Cartagena Protocol; and, most disturbing, alleged human rights violations.
“Free, Prior, Informed Consent interventions by the project included the use of intimidation and fear, driving conflict and dividing communities based on false promises. The limited public participation, dubious tactics, and silencing of communities illustrate its failure to ensure genuine, Free, Prior, and Informed Consent,” submitted CVAB.